First Amendment Suit From Pacira Challenges FDA Labeling Interpretation
This article was originally published in The Pink Sheet Daily
Executive Summary
Speech about specific uses is within broad approved indication of post-surgical pain medication Exparel, Pacira argues.
You may also be interested in...
Pacira's Exparel: US FDA Panel Narrowly Rejects Nerve Block Claim
Inconsistent efficacy data and safety concerns about falls and systemic toxicity lead to advisory committee vote against a labeling expansion for the local anesthetic; Pacira's proposed revisions to the drug's existing infiltration claim also meet some resistance.
Pacira's Exparel Faces Efficacy Questions On Nerve Block Indication
US FDA advisory committee to weigh whether efficacy data support an expanded label for the local anesthetic; despite Pacira's completion of two new studies following a complete response letter, FDA continues to harbor concerns about adequacy of the data to support a broad nerve block claim.
Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review
Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.